Shots:
- Abbott has entered into a definitive agreement to acquire Exact Sciences, making Exact a subsidiary of Abbott upon deal completion
- As per the deal, Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of ~$21B & an estimated enterprise value of $23B, with financing that includes absorbing Exact’s ~$1.8B in net debt; closing expected in Q2’26
- Acquisition will integrate Exact’s portfolio into Abbott’s offerings, incl. Cologuard, a leading noninvasive colorectal cancer screening test, Oncotype DX for personalized breast cancer treatment decisions, Oncodetect for MRD detection & Cancerguard, a multi-cancer early detection blood test
Ref: Abbott | Image: Exact Sciences | Press Release
Related News:- Exact Sciences Launches Cancerguard Test for Early Multi-Cancer Detection
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
